Skip to Main Content

Paper Details

Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer.
Cancer Res
3
2023
B, B-cell malignancies, CAR, CAR T, CAR T cells, CAR T-cell, CRISPR, Cas9, Chimeric Antigen Receptor, Chimeric antigen receptor, INTS12, MSLN, MSLN CAR, MSLN-targeting CAR T cells, NFB transcription factor, Pancreatic Cancer, T, T-cell, TFAP4, Tumor, mesothelin, mesothelin (MSLN)-expressing pancreatic cancer cells, non-B-cell malignancies, p65, pancreatic cancer, pancreatic cancer cells, tumor
Author NameAffiliation
John G DoenchBroad Institute of MIT and Harvard
William C HahnDana-Farber Cancer Institute and Harvard Medical School
William C HahnBroad Institute of MIT and Harvard
William C HahnBrigham and Women's Hospital
William C HahnDana-Farber Cancer Institute and Harvard Medical School
William C HahnBroad Institute of MIT and Harvard
William C HahnBrigham and Women's Hospital
  • 1 - 7

Datasets

Release 1.2